Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-22
2011-03-22
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S250000
Reexamination Certificate
active
07910597
ABSTRACT:
This invention relates to the discovery of 3- and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
REFERENCES:
patent: 1947926 (1934-02-01), Steindorff et al.
patent: 2256999 (1941-09-01), Castner
patent: 2469695 (1949-05-01), McNally
patent: 2608584 (1952-08-01), Sprules et al.
patent: 2732403 (1956-01-01), Surrey
patent: 2862966 (1958-12-01), Surrey
patent: 2883435 (1959-04-01), Welch
patent: 3313854 (1967-04-01), Levy
patent: 3928476 (1975-12-01), Shimada et al.
patent: 3932407 (1976-01-01), Beverung, Jr. et al.
patent: 3983119 (1976-09-01), Beverung, Jr. et al.
patent: 3983120 (1976-09-01), Beverung et al.
patent: 3988340 (1976-10-01), Partyka et al.
patent: 4036838 (1977-07-01), Vogel et al.
patent: 4048168 (1977-09-01), Yamamoto et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4179560 (1979-12-01), Yamamoto et al.
patent: 4202974 (1980-05-01), Yamamoto et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4256748 (1981-03-01), Chodnekar et al.
patent: 4357330 (1982-11-01), Fleming, Jr. et al.
patent: 4390540 (1983-06-01), Chodnekar et al.
patent: 4444777 (1984-04-01), Fleming, Jr. et al.
patent: RE31617 (1984-06-01), Beverung, Jr. et al.
patent: 4455311 (1984-06-01), Kienzle et al.
patent: 4610987 (1986-09-01), Ishikawa et al.
patent: 4808405 (1989-02-01), Smith et al.
patent: 4837239 (1989-06-01), Benjamin et al.
patent: 4847276 (1989-07-01), Yarrington
patent: 5043327 (1991-08-01), Freyne et al.
patent: 5133972 (1992-07-01), Ferrini et al.
patent: 5306709 (1994-04-01), Gewirtz
patent: 5334384 (1994-08-01), Mannix et al.
patent: 5391737 (1995-02-01), Reiter et al.
patent: 5801245 (1998-09-01), Lang
patent: 5874437 (1999-02-01), Garvey et al.
patent: 6024975 (2000-02-01), D'Angelo et al.
patent: 6037346 (2000-03-01), Doherty, Jr. et al.
patent: 6110471 (2000-08-01), Conti et al.
patent: 6156753 (2000-12-01), Doherty, Jr. et al.
patent: 6194420 (2001-02-01), Lang
patent: 6221383 (2001-04-01), Miranda et al.
patent: 6297243 (2001-10-01), Groendahl et al.
patent: 6299900 (2001-10-01), Reed et al.
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6376242 (2002-04-01), Hanson
patent: 6388073 (2002-05-01), Lang et al.
patent: 6403597 (2002-06-01), Wilson et al.
patent: 6548490 (2003-04-01), Doherty, Jr. et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6585995 (2003-07-01), Hanson
patent: 6653500 (2003-11-01), Lang et al.
patent: 2002/0004065 (2002-01-01), Kanios
patent: 2002/0004498 (2002-01-01), Doherty et al.
patent: 2003/0114673 (2003-06-01), Lang
patent: 2003/0134861 (2003-07-01), Doherty et al.
patent: 2003/0181461 (2003-09-01), Lautt et al.
patent: 2004/0014761 (2004-01-01), Place et al.
patent: 2004/0087486 (2004-05-01), Hanson
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0209907 (2004-10-01), Franklin
patent: 2005/0049293 (2005-03-01), Lautt
patent: 2005/0119272 (2005-06-01), Lautt et al.
patent: 2005/0228001 (2005-10-01), Hanson
patent: 2006/0030574 (2006-02-01), Franklin
patent: 2006/0052601 (2006-03-01), Franklin
patent: 2006/0148832 (2006-07-01), Sachse
patent: 2006/0292213 (2006-12-01), Gerber et al.
patent: 2007/0099819 (2007-05-01), Glidden
patent: 2732004 (2005-08-01), None
patent: 2150033 (1994-06-01), None
patent: 2832138 (1979-02-01), None
patent: 19935209 (2001-02-01), None
patent: 0 021 338 (1981-01-01), None
patent: 0046267 (1982-02-01), None
patent: 0054180 (1982-06-01), None
patent: 0 153 152 (1985-08-01), None
patent: 0 205 280 (1986-12-01), None
patent: 0 406 958 (1991-01-01), None
patent: 0 514 917 (1992-11-01), None
patent: 0 546 697 (1993-06-01), None
patent: 994114 (2000-04-01), None
patent: 2001638 (1979-02-01), None
patent: S42-17893 (1967-09-01), None
patent: S42 17893 (1967-09-01), None
patent: S47-19261 (1972-06-01), None
patent: 01258658 (1989-10-01), None
patent: WO-9308798 (1993-05-01), None
patent: WO-9309794 (1993-05-01), None
patent: WO-9428902 (1994-12-01), None
patent: WO-9616644 (1996-06-01), None
patent: WO-9810765 (1998-03-01), None
patent: WO-9938496 (1999-08-01), None
patent: WO-0048636 (2000-08-01), None
patent: WO-0121163 (2001-03-01), None
patent: WO-0121259 (2001-03-01), None
patent: WO-0140196 (2001-06-01), None
patent: WO-0141807 (2001-06-01), None
patent: WO-02/08228 (2002-01-01), None
patent: WO-02062322 (2002-08-01), None
patent: 02096435 (2002-12-01), None
patent: WO-03000343 (2003-01-01), None
patent: WO-03061638 (2003-07-01), None
patent: WO-03061648 (2003-07-01), None
patent: WO-2004012700 (2004-02-01), None
patent: WO-2004037262 (2004-05-01), None
patent: WO-2004043336 (2004-05-01), None
patent: WO-2004043464 (2004-05-01), None
patent: WO-2004/063172 (2004-07-01), None
patent: WO-2004064841 (2004-08-01), None
patent: WO-2005025570 (2005-03-01), None
patent: WO-2005048979 (2005-06-01), None
patent: WO-2005065639 (2005-07-01), None
patent: WO-2006017822 (2006-02-01), None
patent: WO 2010/005480 (2010-01-01), None
Wang, et al., Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures, British J. of Pharmacology, 146, 324-332 (2005).
Agrylin Monograph—Shire 2003—10.
Cohen-Solal et al., Thromb. Haemost. 1997, 78:37-41 -p. 18, I 31 of 5096 and p. 27, I 9 of 3796.
Cramer et al., Blood, 1997, 89:2336-46-p. 18, I 31 of 5096 and p. 27, I 9 of 3796.
Kienzle et al., “1,5-Dihydroimidazoquanizolinones as blood platelet aggregation inhibitors,” Eur. J. Med. Chem. Chim. Ther., 1982, 17:547-556.
Kienzle et al., “Die synthese von 2,3,4,5-1Htetrahydroimidazo-[2,1-b]chinazolin-2,5-dionen und analogen 2,3,4,5-1H-tetrahydroimidazo[1,2-a]thieno[2,3-d](bzw. [3,2-d])-pyrimidin-2,5-dionen,” Helv. Chim. Acta, 1983, 66:148-157.
Martinez et al., “3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.” J. Med. Chem., 1992, 35:620-628.
Meanwell et al., “1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones—inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.” J. Med. Chem., 1991, 34:2906-2916.
Meanwell et al., “Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.” J. Med. Chem., 1992, 35: 2672-2687.
Stalder, “Metaboliten der 1,5-dihydroimidazo[2,1-b]chinazolin-2(3H)-one. Synthese und reaktionen einiger 1,5-dihydro-3-hydroxyimidazo[2,1-b]chinazolin-2(3H)-one,” Helv. Chim. Acta, 1986, 69:1887-1897.
Venuti et al., “Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methy1-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).” J. Med. Chem., 1987, 30:303-318.
Venuti et al., “Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1- b]quinazoline.” J. Med. Chem., 1988, 31:2136-2145.
Citizen Petition, Arnall Golden Gregory LLP, Aug. 13, 2004, 159 pages.
Wagstaff, Antona J. et al., Anagrelide: A Review of its Use in the Management of Essential Thrombocythaemia, Drugs 2006, 66(1):111-131.
Wang, Guosu, et al., “Comparison of the Biological Activities of Anagrelide and its Major Metabolites in Haematopoietic Cell Cultures,” British Journal of Pharmacology 2005, 146:324-332.
Bell, Andrew S., et al. “7-Heteroary1-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2(1H)-one Derivatives with Cardiac Stimulant Activity,” Journal of Medicinal Chemistry, 1989, vol. 32, No. 9, pp. 2042-2049 (8
Franklin Richard
Golding Bernard T.
Frommer & Lawrence & Haug LLP
Fujikawa Shelly M.
Leeser Erich A
Shire LLC
Wilson James O
LandOfFree
Substituted quinazolines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinazolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinazolines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2656097